Overview

PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Status:
Active, not recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

This study is conducted to evaluate the benefit of adding palbociclib in hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer patients, regardless of menopausal status, treated with tamoxifen (with or without goserelin) versus tamoxifen alone (with or without goserelin).

Phase:

Phase 3

Details

Lead Sponsor:

National Cancer Center, Japan

Collaborators:

Korean Cancer Study Group
Pfizer

Treatments:

Goserelin
Hormones
Palbociclib
Tamoxifen